Oncology最新文献

{"title":"Factors relating to Tumor size and survival in patients with hepatocellular carcinoma: significance of PLR, PVT and albumin.","authors":"Rossella Donghia, Brian Irving Carr, Sezai Yilmaz","doi":"10.1159/000545636","DOIUrl":"https://doi.org/10.1159/000545636","url":null,"abstract":"<p><strong>Background and objectives: </strong>Maximum tumor diameter (MTD) is one of the key aggressiveness features of hepatocellular carcinoma (HCC). However, the clinical associations and causes of large size HCC are not well understood. The aims is to compare small and large MTD (≤/> 6cm) HCCs with respect to clinical associations.</p><p><strong>Materials and methods: </strong>MTD ≤/> 6cm HCCs were compared by clinical characteristics and analyzed through logistical regression models, as well as Cox proportional hazard models for death, on clinical parameters.</p><p><strong>Results: </strong>Patients with larger HCCs had more portal vein thrombosis (PVT) and tumor multifocality, higher AST, ALKP and GGT levels and lower albumin levels. A logistic regression model of MTD (≤/> 6cm) showed the highest risk for PVT and platelet-lymphocyte ratio (PLR) >150, while albumin and female gender were protective. Combination male gender, PLR >150 plus PVT had an odds ratio of 12.124. In Cox proportional hazard models, the highest hazard ratio for death was for PVT, and only albumin was significantly protective. PVT plus low albumin had a hazard ratio of 4.254. Conclusions PVT, albumin, PLR and gender were significant for ≤/> 6cm MTD. PVT and albumin were significant for survival.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-19"},"PeriodicalIF":2.5,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143811683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanism research and application prospect of non-coding RNA regulating tumor cell pyroptosis.","authors":"Wang Wan, QiYang Mao, ZhuoHong Ye, Dan Huang, RongJing Zhang, KangXian Wang, XueFeng Wang, QiaYu Wu, ChunYuan Chen, Zhu Liang","doi":"10.1159/000543102","DOIUrl":"https://doi.org/10.1159/000543102","url":null,"abstract":"<p><strong>Background: </strong>Noncoding RNAs (ncRNAs), including microRNAs, lncRNAs, and circRNAs, play essential roles in physiological and pathological processes, including cancer, where they act as drivers or suppressors. Aberrant ncRNA expression in tumors has been linked to tumor promotion or suppression, making them potential cancer biomarkers. Pyroptosis, a newly discovered form of programmed cell death, is characterized by cell swelling, membrane rupture, and inflammation, offering a novel strategy for tumor elimination.</p><p><strong>Summary: </strong>Pyroptosis can activate anti-tumor immunity, while ncRNAs regulate pyroptosis pathways, influencing tumorigenesis through diverse mechanisms. However, the role of ncRNAs in pyroptosis, including potential initiators and their impact on tumor resistance, immunity, and cancer progression, remains unclear. The specific role of circRNAs in pyroptosis also requires further exploration.</p><p><strong>Key messages: </strong>This article explores the role of ncRNAs in pyroptosis, with a particular focus on ncRNA-mediated mechanisms, and highlights their potential as diagnostic and prognostic markers in cancer.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-26"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Histamines Improve the Survival of Lung Cancer: a 10-year Cohort Study of Tertiary Hospital in Taiwan.","authors":"Chun-Hsiang Hsu, Chiu-Fan Chen, Chun-Hao Yin, Yao-Shen Chen, Jin-Shuen Chen","doi":"10.1159/000545458","DOIUrl":"https://doi.org/10.1159/000545458","url":null,"abstract":"<p><strong>Introduction: </strong>Antihistamines (AHs) have beneficial effects as adjuvant anti-cancer agent in several preclinical and observational studies. We aim to evaluate the effect of AHs on stage IV lung cancer patients.</p><p><strong>Materials and methods: </strong>We used data from the Cancer Registry Database provided by the Cancer Center of Kaohsiung Veterans General Hospital to investigate whether AH use is associated with improved survival among patients with stage IV lung cancer. We analyzed AHs use across various patient subgroups, including sex, age, co-morbidities, co-medications, smoking status, histologic type, treatment modality, and survival time. The primary endpoint was overall survival (OS).</p><p><strong>Results: </strong>A total of 1886 lung cancer patients were enrolled. Of them, 41 (2.1%) patients were AH users, 1845 (97.8%) were AH non-users before lung cancer diagnosis, and 594 (31.6%) patients were AH users, 1292 (68.4%) were AH non-users after lung cancer diagnosis. AH users were more to have comorbidities with hypertension (p <0.001), diabetes mellitus (p <0.001), allergic disease (p <0.001), chronic obstructive pulmonary disease (COPD) (p =0.002), and co-medications with targeted therapy (p <0.001), nonaspirin-NSAID (p <0.001). Pre-diagnostic AH users did not show improved survival outcomes. Post-diagnostic AH users tend to have a better OS among patients with a survival period of more than 90 days (median, 28.4 months and 15.1 months, respectively; HR 0.49; 95% confidence interval 0.43-0.55) Conclusions: AHs use was associated with improved OS in patients with stage IV lung cancer. Further prospective studies are needed to better elucidate the role of AHs in the treatment of lung cancer.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-21"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in tumor-infiltrating lymphocytes and inflammatory blood factors during CRT in rectal cancer.","authors":"Hiroshi Miyakita, Takashi Ogimi, Hajime Kayano, Masaki Mori, Seiichiro Yamamoto","doi":"10.1159/000545312","DOIUrl":"https://doi.org/10.1159/000545312","url":null,"abstract":"<p><strong>Introduction: </strong>Multidisciplinary treatments for advanced rectal cancer are diverse. Neoadjuvant chemoradiation therapy (nCRT) is a total neoadjuvant therapy treatment option. Some studies have reported that tumor-infiltrating lymphocytes (TILs) and inflammatory blood factors [(neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune inflammatory index (SII)] are predictors of nCRT efficacy. However, the relationship between changes in TILs and inflammatory blood factors during nCRT and the resulting tumor regression grade (TRG) remains unclear. In this study, we investigated whether changes in TILs and inflammatory blood factors during nCRT were related to TRG.</p><p><strong>Methods: </strong>We retrospectively studied 196 patients with rectal cancer who underwent curative resection after nCRT for advanced rectal cancer. Immunohistochemical staining of lymphocyte surface markers, including CD3, CD4, and CD8, was performed on biopsy specimens before and during nCRT. Inflammatory blood factors were assessed using blood samples collected before treatment and seven days after the initiation of nCRT.</p><p><strong>Results: </strong>Changes in CD4 levels were related to TRG. NLR and SII during nCRT were associated with TRG. TRG tended to be better in patients with values below the cut-off. The NLR during nCRT and changes in NLR, PLR, and SII were associated with the tumor shrinkage rate. Changes in PLR were related to TRG. There was no relationship between TIL, peripheral blood changes, and recurrence rate.</p><p><strong>Conclusion: </strong>It was suggested that changes in CD4+ TILs immediately after treatment initiation and changes in inflammatory blood factors during treatment may be useful for predicting the reduction rate and TRG. These changes begin early during treatment and may be useful in predicting efficacy.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-20"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Social Vulnerability Index on Multiple Myeloma Mortality.","authors":"Jia Yi Tan, Boon Jian San, Tze Ern Ong, Yong Hao Yeo, Modupe Idowu","doi":"10.1159/000545459","DOIUrl":"https://doi.org/10.1159/000545459","url":null,"abstract":"<p><p>Introduction The incidence of multiple myeloma (MM) in the United States has been increasing over the past decades with persistent demographic disparities. Social determinants of health (SDOH) were found to affect health outcomes among certain diseases. However, there was limited data on the impact of SDOH on the MM mortality rates. Our study aimed to investigate the association between the SDOH and MM mortality rates from 2016 to 2020. Methods County-level data from the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry Social Vulnerability Index (CDC/ATSDR SVI) were correlated with MM mortality rates from the CDC WONDER database. Counties were categorized into four quartiles based on SVI scores: SVI-Q1 (lowest vulnerability) to SVI-Q4 (highest vulnerability). Age-adjusted mortality rates (AAMRs) per 100,000 individuals for patients aged 25 years and above were analyzed. Rate ratio (RD) was measured by calculating the ratio of the AAMRs in SVI-Q4 to SVI-Q1. Results Between 2016 and 2020, 61,307 MM-related deaths occurred, with 20,390 in SVI-Q4 versus 8,498 in SVI-Q1. Overall, AAMR was higher in SVI-Q4 (4.90; 95% CI, 4.83-4.97) than in SVI-Q1 (4.66; 95% CI, 4.56-4.76), though the RR was not significant (1.05; 95% CI, 0.81-1.36). Higher SVI was not significantly associated with higher AAMR among males (RR: 1.03; 95% CI, 0.73-1.45) or females (RR: 1.10; 95% CI, 0.75-1.62), Among the younger patients (25 - 64 years old) and the older patients (65 years old and above), increasing SVI was not associated with higher AAMR (RR: 1.27 [95% CI, 0.69 - 2.34] and 1.01 [95%, 0.76 - 1.34] respectively). SVI was also not significantly associated with higher AAMR in the rural populations (1.07 [95% CI, 0.60-1.92]). Across racial groups-American Indians, Asians, African Americans, Hispanics, and Whites-SVI was not significantly associated with AAMR differences. Similarly, no significant differences were observed when stratified by census regions (Northeast, Midwest, South, and West). Conclusion African Americans had higher AAMRs from MM compared to other racial groups. However, SVI scores were not significantly associated with MM mortality disparities. These findings suggest that SVI alone is insufficient to determine mortality disparities in MM. Future research should explore more specific indicators to identify at-risk populations and address mortality inequities in MM.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-11"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modified Glasgow prognostic score as a marker for predicting outcomes in patients with either bladder and prostate cancer : A systematic review and meta-analysis.","authors":"Jie Chen, Suna Fu, Jianhong Yu, Qi Tang, Xiuping Wu, Sai Luo, Huifang Sun","doi":"10.1159/000545001","DOIUrl":"https://doi.org/10.1159/000545001","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association of pretreatment-modified Glasgow Prognostic Score (mGPS) with survival-related outcomes in patients with bladder cancer (BC) and prostate cancer (PC).</p><p><strong>Methods: </strong>A systematic search was performed in PubMed, EMBASE, Web of Science, and Scopus databases for cohort studies in adult participants (≥18 years). The exposure was pre-treatment mGPS and the outcomes of interest were overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Eligible studies compared low mGPS (considered as a score of 0) with a score of ≥1. A random effects model was used for the analysis. Pooled effect sizes were reported as hazard ratio (HR) with 95% confidence intervals (CI). Subgroup analysis was performed based on the tumour stage (≤T2 and >T2), sample size (≥200 and <200), treatment (surgical and non-surgical), and the Newcastle-Ottawa Scale (NOS) score (≥8 and ≤7).</p><p><strong>Results: </strong>Of 20 studies. Included in the analysis, 19 studies were retrospective cohort studies. Fourteen studies reported data of patients with BC, and the remaining 6 studies focused on PC patients. Compared to mGPS of 0, higher scores were associated with reduced OS (HR 2.65, 95% CI: 1.99, 3.52), CSS (HR 1.64, 95% CI: 1.19, 2.26), and RFS (HR 1.77, 95% CI: 1.50, 2.08). There was no evidence of publication bias (Egger's p>0.05). These associations remained valid in subgroup analysis.</p><p><strong>Conclusion: </strong>Higher mGPS values were found to be associated with significantly reduced survival outcomes. These findings underscore the prognostic significance of mGPS, thereby highlighting its potential clinical utility in risk stratification and treatment decision-making.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-20"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy.","authors":"Khanh Van Nguyen, Kosuke Matsui, Hisashi Kosaka, Hideyuki Matsushima, Hidekazu Yamamoto, Tung Thanh Lai, Kyoko Inoue, Moriyasu Takada, Fujimasa Tada, Atsushi Hiraoka, Takeshi Hatanaka, Toshifumi Tada, Takashi Kumada, Hiroki Kato, Kengo Yoshii, Takashi Yamaguchi, Shinji Shimoda, Makoto Naganuma, Masaki Kaibori","doi":"10.1159/000544979","DOIUrl":"https://doi.org/10.1159/000544979","url":null,"abstract":"<p><strong>Background and aim: </strong>We investigated the association between the pretreatment cachexia index (CXI) and survival outcomes in patients with unresectable hepatocellular carcinoma (u-HCC) receiving atezolizumab plus bevacizumab (Atez/Bev).</p><p><strong>Methods: </strong>We conducted a retrospective analysis of 195 patients with u-HCC treated with Atez/Bev from September 2020 to December 2023. The skeletal muscle mass index (SMI) was calculated by normalizing the psoas muscle area by the square of the height (cm²/m²). The CXI was defined as the SMI × serum albumin level (g/dL)/neutrophil-to-lymphocyte ratio. Propensity score matching (PSM) was applied to minimize the effect of potential confounders. Associations between CXI, overall survival (OS), and progression-free survival (PFS) were assessed.</p><p><strong>Results: </strong>From the initial cohort, CXI cutoffs of 7.23 for males and 4.99 for females were established. PSM matched 60 pairs of patients with low and high CXI, showing no significant differences in confounding factors between groups. Kaplan-Meier analysis indicated that the low-CXI group had shorter median OS (12.5 versus 26.1 months, p = 0.009) and PFS (6.1 versus 11.1 months, p = 0.045) compared with the high-CXI group. No significant differences existed between groups in overall response rate (p = 0.994) and disease control rate (p = 0.090). Multivariate Cox proportional hazards analysis identified low CXI as an independent prognostic factor for OS (HR: 1.89, 95% CI: 1.11-3.22, p = 0.019) and PFS (HR: 1.53, 95% CI: 1.01-2.34, p = 0.047).</p><p><strong>Conclusions: </strong>The CXI may be a valuable prognostic tool for predicting survival outcomes in patients with u-HCC receiving Atez/Bev.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-21"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study.","authors":"Takanori Suzuki, Kiyoto Narita, Kentaro Matsuura, Daisuke Kato, Katsumi Hayashi, Kohei Okayama, Fumihiro Okumura, Satoshi Sobue, Atsunori Kusakabe, Izumi Hasegawa, Tsutomu Mizoshita, Yoshihide Kimura, Hiromu Kondo, Atsushi Ozasa, Hayato Kawamura, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka","doi":"10.1159/000544051","DOIUrl":"https://doi.org/10.1159/000544051","url":null,"abstract":"<p><strong>Introduction: </strong>Changes in liver function in patients with unresectable hepatocellular carcinoma (u-HCC), following extended periods from the initiation of atezolizumab plus bevacizumab (Atez/Bev), have not been fully investigated.</p><p><strong>Methods: </strong>Of 148 u-HCC patients treated with first-line Atez/Bev, the study enrolled 38 u-HCC patients treated with first-line Atez/Bev, whose treatment response was initially evaluated as non-progressive disease (non-PD) and later as PD on imaging, and who then received second-line systemic chemotherapy. We evaluated the relationship between the period from the initiation of first-line Atez/Bev to that of second-line systemic chemotherapy with liver function and prognosis.</p><p><strong>Results: </strong>According to the periods from the initiation of Atez/Bev to that of the second-line therapy, patients were classified into a long continuation group (Group-L, n = 19), ≥11 months; or a short continuation group (Group-S, n = 19), <11 months. The albumin-bilirubin (ALBI) score at the initiation of the second-line therapy did not differ significantly between the groups (median: -2.38 vs. -2.02, p = 0.559), and the change in ALBI score also did not differ significantly between the groups (median: 0.42 vs. 0.51, p = 0.770). Group-L had significantly better overall survival (OS) than Group-S (not reached vs. 18 months, p = 0.008).</p><p><strong>Conclusions: </strong>Liver function did not decrease even after long-term treatment with first-line Atez/Bev in patients who were able to progress to second-line therapy, indicating that long continuation of first-line Atez/Bev may be valuable for improving OS.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.5,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atezolizumaba plus bevacizumab is Associated with Favorable Overall Survival Over Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.","authors":"Hyung-Don Kim, Young-Gyu Park, Hyeyeon Hong, Sung Won Chung, Sejin Kim, Min-Hee Ryu, Baek-Yeol Ryoo, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Won-Mook Choi, Changhoon Yoo","doi":"10.1159/000545351","DOIUrl":"https://doi.org/10.1159/000545351","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare the effectiveness outcomes of Child-Pugh class A patients with unresectable hepatocellular carcinoma (HCC) treated with first-line atezolizumab-bevacizumab and lenvatinib.</p><p><strong>Methods: </strong>This retrospective study included patients with Child-Pugh A unresectable HCC who were administered first-line treatment with either atezolizumab-bevacizumab (n = 368) or lenvatinib (n = 229) at Asan Medical Center (Seoul, Korea). Effectiveness outcomes were analyzed along with the inverse probability treatment weighting (IPTW) analysis to adjust for potential confounders.</p><p><strong>Results: </strong>Hepatitis B virus infection was the most common cause of HCC. With median follow-up duration of 11.9 for atezolizumab-bevacizumab and 20.9 months for the lenvatinib groups, patients treated with atezolizumab-bevacizumab exhibited superior progression-free survival (PFS) and overall survival (OS) than those treated with lenvatinib (median PFS 6.3 vs. 4.9 months, P = 0.031; and median OS 18.5 vs. 11.3 months, P < 0.001). After IPTW adjustment, atezolizumab-bevacizumab remained associated with favorable OS (median OS of 17.9 vs. 12.3 months, P = 0.010). Treatment with atezolizumab-bevacizumab was an independent factor of OS in both the entire and IPTW-adjusted cohorts. For patients with a viral etiology, the atezolizumab-bevacizumab group exhibited significantly longer OS than the lenvatinib group in both entire and IPTW-adjusted cohorts (P < 0.001 and P = 0.006, respectively). Conversely, both groups showed comparable OS among those with a nonviral etiology (P = 0.656 and P = 0.616, respectively).</p><p><strong>Conclusions: </strong>Atezolizumab-bevacizumab showed superior OS compared to lenvatinib in Asian patients with unresectable HCC.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-22"},"PeriodicalIF":2.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of the new category by number of stations for lymph nodal involvement in non-small cell lung cancer.","authors":"Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima, Hidetaka Uramoto","doi":"10.1159/000545002","DOIUrl":"https://doi.org/10.1159/000545002","url":null,"abstract":"<p><strong>Introduction: </strong>In the nineth edition of the TNM staging system, the new nodal involvement (N) subcategories to N2 for single-station involvement (N2a) and multiple-station involvement (N2b) has been adopted Although there are significant differences in survival rates for each group of pN categories in the nineth edition, it can be assumed that survival rates in pN1 and pN2a are relatively similar.</p><p><strong>Methods: </strong>We retrospectively evaluated the utility of the new category by number of stations, such as None, Single station, and Multiple station for pN in 1000 NSCLC patients treated by pulmonary resection.</p><p><strong>Result: </strong>Survival rates were significantly different in among None, Single station, and Multiple station (5-year RFS: None;79.6%, Single station;47.3%, Multiple station;24.2%, all groups p<0.01. 8-year OS: None;78.7%, Single station;65.2%, Multiple station;33.6%, all groups p<0.01). There were significant differences among each group categorized by number of pN station in multivariate analysis for RFS (None vs Single station; P<.01, None vs Multiple station; P<.01, Single station vs Multiple station; P<.01). There were significant differences among each group categorized by number of pN station in multivariate analysis for OS (None vs Single station; P=.04, None vs Multiple station; P<.01, Single station vs Multiple station; P<.01).</p><p><strong>Conclusion: </strong>There were significant differences among None, Single station, and Multiple station in each survival curves, and in multivariate analysis for both RFS and OS. This category by number of pN station without dependence of location for lymph nodal involvement might be the new classification of lymph node involvement.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-24"},"PeriodicalIF":2.5,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}